NO310854B1 - Anvendelse av mometasonfuroat og salisylsyre for fremstilling av et farmasoytisk preparat, samt et farmasoytisk preparat inneholdende disse - Google Patents
Anvendelse av mometasonfuroat og salisylsyre for fremstilling av et farmasoytisk preparat, samt et farmasoytisk preparat inneholdende disse Download PDFInfo
- Publication number
- NO310854B1 NO310854B1 NO19962619A NO962619A NO310854B1 NO 310854 B1 NO310854 B1 NO 310854B1 NO 19962619 A NO19962619 A NO 19962619A NO 962619 A NO962619 A NO 962619A NO 310854 B1 NO310854 B1 NO 310854B1
- Authority
- NO
- Norway
- Prior art keywords
- mometasone furoate
- salicylic acid
- ointment
- psoriasis
- pharmaceutical composition
- Prior art date
Links
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 title claims abstract description 98
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 title claims abstract description 62
- 229960002744 mometasone furoate Drugs 0.000 title claims abstract description 53
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 title claims abstract description 48
- 229960004889 salicylic acid Drugs 0.000 title claims abstract description 48
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 238000002360 preparation method Methods 0.000 title description 7
- 238000011282 treatment Methods 0.000 claims abstract description 47
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 39
- 208000017520 skin disease Diseases 0.000 claims abstract description 17
- 230000000699 topical effect Effects 0.000 claims abstract description 12
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 7
- 230000001329 hyperkeratotic effect Effects 0.000 abstract 2
- 239000002674 ointment Substances 0.000 description 50
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 229940073610 elocon Drugs 0.000 description 9
- 230000003902 lesion Effects 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 7
- 206010015150 Erythema Diseases 0.000 description 6
- 229940051250 hexylene glycol Drugs 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000003246 corticosteroid Substances 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229960000785 fluocinonide Drugs 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000004761 scalp Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000004797 therapeutic response Effects 0.000 description 3
- 206010048768 Dermatosis Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000011280 coal tar Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000009605 Hand Dermatoses Diseases 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- 206010024438 Lichenification Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940030999 antipsoriatics Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960002311 dithranol Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 201000010113 hand dermatosis Diseases 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000018040 scab formation Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126702 topical medication Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
- A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17105193A | 1993-12-21 | 1993-12-21 | |
| PCT/US1994/014165 WO1995017196A1 (fr) | 1993-12-21 | 1994-12-19 | Traitement du psoriasis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO962619D0 NO962619D0 (no) | 1996-06-20 |
| NO962619L NO962619L (no) | 1996-06-20 |
| NO310854B1 true NO310854B1 (no) | 2001-09-10 |
Family
ID=22622295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19962619A NO310854B1 (no) | 1993-12-21 | 1996-06-20 | Anvendelse av mometasonfuroat og salisylsyre for fremstilling av et farmasoytisk preparat, samt et farmasoytisk preparat inneholdende disse |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0735885B1 (fr) |
| JP (2) | JP3830963B2 (fr) |
| KR (1) | KR100361240B1 (fr) |
| CN (1) | CN1055392C (fr) |
| AT (1) | ATE271896T1 (fr) |
| AU (1) | AU701833B2 (fr) |
| CA (1) | CA2179628C (fr) |
| CZ (1) | CZ283932B6 (fr) |
| DE (1) | DE69433923T2 (fr) |
| ES (1) | ES2221928T3 (fr) |
| FI (1) | FI117001B (fr) |
| HK (1) | HK1008814A1 (fr) |
| HU (1) | HU226621B1 (fr) |
| IL (1) | IL112019A (fr) |
| MY (1) | MY111719A (fr) |
| NO (1) | NO310854B1 (fr) |
| NZ (1) | NZ278198A (fr) |
| PL (1) | PL178427B1 (fr) |
| SK (1) | SK280766B6 (fr) |
| TW (1) | TW442281B (fr) |
| WO (1) | WO1995017196A1 (fr) |
| ZA (1) | ZA9410143B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19736265C2 (de) * | 1997-08-15 | 2002-10-31 | Phytexpert Pharm Tox Consultin | Arzneimittel zur Behandlung von Hauterkrankungen |
| WO2000012096A1 (fr) * | 1998-08-26 | 2000-03-09 | Shionogi & Co., Ltd. | Pommades anti-inflammatoires |
| GR1006093B (el) * | 2007-09-07 | 2008-10-06 | Γεωργιος Καλλιμανης | Παρασκευη φαρμακου με δραστικο συστατικο ουρσολικο οξυ (ursolic acid) για την θεραπεια ψωριασης |
| WO2010048675A1 (fr) * | 2008-10-30 | 2010-05-06 | Ego Pharmaceuticals Pty Ltd | Compositions pharmaceutiques anti-inflammatoires comprenant un corticostéroïde, de l'hexylène glycol et de l'eau |
| EP2394653A1 (fr) | 2010-05-26 | 2011-12-14 | Almirall, S.A. | Compositions pharmaceutiques topiques contenant du furoate de mométasone |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4579844A (en) * | 1976-05-13 | 1986-04-01 | Johnson & Johnson | Topical anti-inflammatory drug therapy |
| DE2744826A1 (de) * | 1976-10-06 | 1978-04-13 | Marques Brev Soc Et Exploit | Therapeutische zubereitung |
| EP0057401B1 (fr) * | 1981-02-02 | 1984-08-01 | Schering Corporation | Esters aromatiques hétérocycliques de stéroides, leur préparation et compositions pharmaceutiques les contenant |
| YU46838B (sh) * | 1986-02-14 | 1994-06-24 | Pero Dr. Višnjić | Postupak za dobijanje preparata za lečenje kožne bolesti psoriazisa |
| US4808610A (en) * | 1986-10-02 | 1989-02-28 | Schering Corporation | Mometasone furoate anti-inflammatory cream composition using hexylene glycol |
| US4775529A (en) * | 1987-05-21 | 1988-10-04 | Schering Corporation | Steroid lotion |
| US5061700A (en) * | 1989-11-16 | 1991-10-29 | Gordon Jay Dow | Glyceryl acetate ointment vehicles |
-
1994
- 1994-12-19 HU HU9601708A patent/HU226621B1/hu unknown
- 1994-12-19 CN CN94194601A patent/CN1055392C/zh not_active Expired - Lifetime
- 1994-12-19 JP JP51746295A patent/JP3830963B2/ja not_active Expired - Lifetime
- 1994-12-19 PL PL94315150A patent/PL178427B1/pl unknown
- 1994-12-19 WO PCT/US1994/014165 patent/WO1995017196A1/fr active IP Right Grant
- 1994-12-19 EP EP95905880A patent/EP0735885B1/fr not_active Expired - Lifetime
- 1994-12-19 CA CA002179628A patent/CA2179628C/fr not_active Expired - Lifetime
- 1994-12-19 IL IL11201994A patent/IL112019A/xx not_active IP Right Cessation
- 1994-12-19 AT AT95905880T patent/ATE271896T1/de not_active IP Right Cessation
- 1994-12-19 NZ NZ278198A patent/NZ278198A/en not_active IP Right Cessation
- 1994-12-19 AU AU14328/95A patent/AU701833B2/en not_active Expired
- 1994-12-19 KR KR1019960703235A patent/KR100361240B1/ko not_active IP Right Cessation
- 1994-12-19 DE DE69433923T patent/DE69433923T2/de not_active Expired - Lifetime
- 1994-12-19 CZ CZ961784A patent/CZ283932B6/cs not_active IP Right Cessation
- 1994-12-19 SK SK818-96A patent/SK280766B6/sk not_active IP Right Cessation
- 1994-12-19 ES ES95905880T patent/ES2221928T3/es not_active Expired - Lifetime
- 1994-12-19 TW TW083111877A patent/TW442281B/zh not_active IP Right Cessation
- 1994-12-20 ZA ZA9410143A patent/ZA9410143B/xx unknown
- 1994-12-20 MY MYPI94003429A patent/MY111719A/en unknown
-
1996
- 1996-06-17 FI FI962506A patent/FI117001B/fi not_active IP Right Cessation
- 1996-06-20 NO NO19962619A patent/NO310854B1/no not_active IP Right Cessation
-
1998
- 1998-07-29 HK HK98109524A patent/HK1008814A1/xx not_active IP Right Cessation
-
2005
- 2005-03-01 JP JP2005056723A patent/JP2005139210A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fredriksson et al. | Urea creams in the treatment of dry skin and hand dermatitis. | |
| US6096326A (en) | Skin care compositions and use | |
| KR20050089740A (ko) | 주사 치료를 위한 국소적 제형 | |
| EP1867322B1 (fr) | Composition topique pour le traitement du psoriasis | |
| JP2015530380A (ja) | 乾癬を治療するための組成物 | |
| Stein et al. | Betamethasone valerate foam for treatment of nonscalp psoriasis | |
| JP2005139210A (ja) | 乾癬治療 | |
| Marinho et al. | Clinical efficacy and safety profile of topical etofenamate in the treatment of patients with musculoskeletal disorders: a systematic review | |
| JPH03227921A (ja) | ケロイド治療剤 | |
| JPH06199672A (ja) | 活性成分としてクロラムフェニコール、ゲンタマイシンおよびナイスタチンを含有する、炎症性皮膚疾患の局所治療のための配合製剤 | |
| EP4041186A1 (fr) | Composition pharmaceutique anhydre pour le traitement de l'entretien du psoriasis | |
| JPS62155214A (ja) | 炎症治療薬及びそれによる炎症治療方法 | |
| EP2934520A1 (fr) | Utilisation du pidotimod pour traiter la dermatite atopique | |
| RU2517520C1 (ru) | Средство наружной терапии для больных атопическим дерматитом | |
| Shenenberger | Curbing the psoriasis cascade: Therapies to minimize flares and frustration | |
| Bhatia et al. | ATIN Ps0RIASIS: AN UPDATE | |
| Chaplin et al. | Xamiol: betamethasone plus calcipotriol for scalp psoriasis | |
| KR20020035131A (ko) | 덱스라족산의 건선 치료 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: MERCK SHARP AND DOHME CORP Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY, US |
|
| MK1K | Patent expired |